Ventus therapeutics enters exclusive development and license agreement with novo nordisk for nlrp3 inhibitor program

Waltham, mass. & montreal--(business wire)--ventus therapeutics, inc., a biopharmaceutical company utilizing structural biology and a proprietary computational chemistry platform to identify and develop small molecule therapeutics across a broad range of diseases, announced today that the company has entered into an exclusive worldwide license agreement with novo nordisk a/s to develop and commercialize candidates from ventus' portfolio of peripherally-restricted nlrp3 inhibitors. “this is an i
NVO Ratings Summary
NVO Quant Ranking